Neutrophil-Lymphocyte Ratio, Platelet Lymphocyte Ratio, And Carcinoembryonic Antigen Relationship With Survival In Non-Small Cell Lung Cancer Patients

Haryati Haryati (1), Ayudiah Puspita Mayasari (2), Farida Heriyani (3)
(1) a:1:{s:5:"en_US";s:165:"Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University/Ulin General Hospital, Banjarmasin, South Kalimantan, Indonesia";}, Indonesia,
(2) Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University/Ulin General Hospital, Banjarmasin, South Kalimantan, Indonesia, Indonesia,
(3) Department of Public Health Science, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia, Indonesia

Abstract

Inflammation is crucial to cancer development. A complete blood count is standard patient testing. Thus, inflammatory biomarkers like neutrophil-lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) may predict lung cancer prognosis. Serum carcinoembryonic antigen (CEA) is the main predictive marker of most studies. Elevated NLR, PLR, and CEA levels are frequently associated with poorer overall survival in NSCLC patients. A retrospective cross-sectional study included 50 NSCLC medical records patients from Ulin Regional South Kalimantan Hospital. NLR, PLR, and CEA baseline peripheral blood individuals were investigated for NSCLC overall survival (OS). Patients are separated by OS mean into two groups. Mann-Whitney compared variables. The ROC curve and AUC were used to evaluate the above indicators' prognostic value. The mean of OS was 6 months. NLR, PLR, and CEA patients in ≤ 6 months had higher median values compared to > 6 months groups (8.73 vs. 4.3; 301.23 vs. 217.81; and 106 vs. 27.87). Survival was significantly associated with NLR and CEA (p-values 0.010 and 0.011). NLR >5.90 with AUC 0.725 (sensitivity 63.6%, specificity 29.4%) and CEA >41.39 ng/mL with AUC 0.722 (sensitivity 72.7%, specificity 29.4%). Parallel tests of NLR and CEA testing increased sensitivity and specificity (75.8%, 70.6%). This study revealed that elevated NLR and CEA are associated with patient survival, and monitoring both markers enhances survival prediction accuracy. It can improve insight into disease progression and adjust the therapeutic approach for NSCLC patients.

Full text article

Generated from XML file

References

Anderson, R., Rapoport, B. L., Steel, H. C., & Theron, A. J. (2023). Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer. International Journal of Molecular Sciences, 24(15). https://doi.org/10.3390/ijms241511927

Arrieta, O., Varela-Santoyo, E., Cardona, A. F., Sánchez-Reyes, R., Lara-Mejía, L., Bassarmal, S. S., Valle-Bautista, D., Corrales-Rodríguez, L., Motola-Kuba, D., Cabrera-Miranda, L., & Martín, C. (2021). Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clinical Lung Cancer, 22(6), 510–522. https://doi.org/10.1016/j.cllc.2021.03.014

Cheng, L., Yin, R., Yu, Y., Yang, D., & Xu, L. (2019). Prognostic value of carcinoembryonic antigen level in advanced lung adenocarcinoma. Int J Clin Exp Med, 12(5), 5812–5819. www.ijcem.com/

Ding, N., Pang, Z., Shen, H., Ni, Y., Du, J., & Liu, Q. (2016). The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort. Scientific Reports, 6(October), 1–9. https://doi.org/10.1038/srep34823

Faot, N. E., & Pradjoko, I. (2017). Rasio Neutrofil-Limfosit Sebelum Kemoterapi dan Respons Obyektif Kemoterapi Pasien Kanker Paru dengan Kemoterapi Berbasis Platinum Correlation Between Neutrofil-Limphocyte Ratio Before Chemoteraphy and Objective Response Platinum based Chemoteraphy on Lun. Jurnal Respirologi Indonesia, 37(4), 293–301.

Gupta, D. A., Singh, D. U., Lal Gupta, D. M., Mogra, D. N., & Mathur, D. M. (2019). Significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in lung cancer. Tropical Journal of Pathology and Microbiology, 5(11), 872–877. https://doi.org/10.17511/jopm.2019.i11.07

Hardtstock, F., Myers, D., Li, T., Cizova, D., Maywald, U., Wilke, T., & Griesinger, F. (2020). Real-world treatment and survival of patients with advanced non-small cell lung Cancer: A German retrospective data analysis. BMC Cancer, 20(1), 1–14. https://doi.org/10.1186/s12885-020-06738-z

Haryati, Bakhriansyah, M., & Aisah, S. K. N. (2013). Profil Penderita Kanker Paru Primer di Rumah Sakit Umum Daerah Ulin Banjarmasin Tahun 2006-2011. Jurnal Respi Indo, 33(1), 50–56.

Jabłońska, I., Miszczyk, M., Goławski, M., Dębosz-Suwińska, I., & Suwiński, R. (2022). The prognostic value of RDW, NLR and PLR in sequential radio-chemotherapy for advanced lung cancer. Nowotwory, 72(3), 161–166. https://doi.org/10.5603/NJO.a2022.0010

Kangkhetkron, T., & Juntarawijit, C. (2024). Pesticide exposure and lung cancer risk: A case-control study in Nakhon Sawan, Thailand. F1000Research, 9, 1–43. https://doi.org/10.12688/f1000research.24114.8

Lim, J. U., Yeo, C. D., Kang, H. S., Park, C. K., Kim, J. S., Kim, J. W., Kim, S. J., & Lee, S. H. (2019). Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. Scientific Reports, 9(1), 1–8. https://doi.org/10.1038/s41598-019-41289-9

Ozyurek, B. A., Ozdemirel, T. S., Ozden, S. B., Erdogan, Y., Kaplan, B., & Kaplan, T. (2017). Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. Asian Pacific Journal of Cancer Prevention, 18(5), 1417–1421. https://doi.org/10.22034/APJCP.2017.18.5.1417

Putra, D. H., Wulandari, L., & Mustokoweni, S. (2016). Profil penderita kanker paru karsinoma bukan sel kecil (kpkbsk) di rsud dr. soetomo. UXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga, 8(1), 31–33.

Sanikini, H., Yuan, J. M., Butler, L. M., Koh, W. P., Gao, Y. T., Steffen, A., Johansson, M., Vineis, P., Goodman, G. E., Barnett, M. J., Hung, R. J., Chen, C., & Stücker, I. (2018). Body mass index and lung cancer risk: A pooled analysis based on nested case-control studies from four cohort studies. BMC Cancer, 18(1), 1–10. https://doi.org/10.1186/s12885-018-4124-0

Shankar, A., Dubey, A., Saini, D., Singh, M., Prasad, C. P., Roy, S., Bharati, S. J., Rinki, M., Singh, N., Seth, T., Khanna, M., Sethi, N., Kumar, S., Sirohi, B., Mohan, A., Guleria, R., & Rath, G. K. (2019). Environmental and occupational determinants of lung cancer. Translational Lung Cancer Research, 8(Suppl 1), S31–S49. https://doi.org/10.21037/tlcr.2019.03.05

Song, M., Zhang, Q., Song, C., Liu, T., Zhang, X., Ruan, G., Tang, M., Xie, H., Zhang, H., Ge, Y., Li, X., Zhang, K., Yang, M., Li, Q., Liu, X., Lin, S., Xu, Y., Xu, H., Wang, K., … Shi, H. (2022). The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. Journal of Cachexia, Sarcopenia and Muscle, 13(5), 2504–2514. https://doi.org/10.1002/jcsm.13032

Song, X., Chen, D., Yuan, M., Wang, H., & Wang, Z. (2018). Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy. Cancer Management and Research, 10, 6677–6683. https://doi.org/10.2147/CMAR.S188578

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

Travis, W. D. (2020). Lung Cancer Pathology: Current Concepts. Clinics in Chest Medicine, 41(1), 67–85. https://doi.org/10.1016/j.ccm.2019.11.001

Wang, Z., Zhan, P., Lv, Y., Shen, K., Wei, Y., Liu, H., & Song, Y. (2019). Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: A meta-analysis. Translational Lung Cancer Research, 8(3), 214–226. https://doi.org/10.21037/tlcr.2019.06.10

Wao, H., Mhaskar, R., Kumar, A., Miladinovic, B., & Djulbegovic, B. (2013). Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Systematic Reviews, 2(1), 10. https://doi.org/10.1186/2046-4053-2-10

Yin, Y., Wang, J., Wang, X., Gu, L., Pei, H., Kuai, S., Zhang, Y., & Shang, Z. (2015). Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. Clinics, 70(7), 524–530. https://doi.org/10.6061/clinics/2015(07)10

Zhang, Z. H., Han, Y. W., Liang, H., & Wang, L. M. (2015). Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Medicine, 4(11), 1633–1638. https://doi.org/10.1002/cam4.493

Zhao, X. M., Zhao, J., Xing, K. L., Sun, S., Luo, Z. G., Wang, H. J., Wang, J. L., Chang, J. H., & Wu, X. H. (2017). Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors. Oncotarget, 8(41), 70865–70873. https://doi.org/10.18632/oncotarget.20145

Authors

Haryati Haryati
haryati@ulm.ac.id (Primary Contact)
Ayudiah Puspita Mayasari
Farida Heriyani
Haryati, H., Mayasari, A. P., & Heriyani, F. Neutrophil-Lymphocyte Ratio, Platelet Lymphocyte Ratio, And Carcinoembryonic Antigen Relationship With Survival In Non-Small Cell Lung Cancer Patients. Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya, 9(01). https://doi.org/10.30651/jqm.v9i01.22773

Article Details

No Related Submission Found